The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
The funding will accelerate Sinopia’s data-driven drug discovery efforts
Applications include detailed scientific rationale and supporting clinical evidence
Under his leadership, Chidamide became China’s first original small-molecule anti-tumor innovative drug and the country’s first pharmaceutical product globally licensed out
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
Subscribe To Our Newsletter & Stay Updated
